Replimune Group, Inc. REPL
We take great care to ensure that the data presented and summarized in this overview for Replimune Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding REPL
View all-
Baker Bros. Advisors LP New York, NY11MShares$99.3 Million0.38% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.31MShares$74.7 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY6.4MShares$57.5 Million0.36% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$42.4 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.16MShares$37.4 Million3.48% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.63MShares$32.6 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.48MShares$31.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.4MShares$30.6 Million0.65% of portfolio
-
State Street Corp Boston, MA2.92MShares$26.3 Million0.0% of portfolio
-
Braidwell LP Stamford, CT2.75MShares$24.7 Million0.66% of portfolio
Latest Institutional Activity in REPL
Top Purchases
Top Sells
About REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Insider Transactions at REPL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Kapil Dhingra Director |
SELL
Open market or private sale
|
Direct |
3,169
-100.0%
|
$31,690
$10.4 P/Share
|
|
Dec 09
2025
|
Kapil Dhingra Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,169
+50.0%
|
$3,169
$1.75 P/Share
|
|
Dec 02
2025
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-2.91%
|
$110,000
$11.13 P/Share
|
|
Nov 17
2025
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,248
-4.93%
|
$65,232
$9.1 P/Share
|
|
Nov 17
2025
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,208
-4.06%
|
$46,872
$9.1 P/Share
|
|
Aug 15
2025
|
Emily Luisa Hill Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,154
-6.38%
|
$45,770
$5.37 P/Share
|
|
May 20
2025
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,105
-6.81%
|
$200,840
$8.06 P/Share
|
|
May 20
2025
|
Andrew Schwendenman Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,287
-4.59%
|
$26,296
$8.05 P/Share
|
|
May 20
2025
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,952
-5.13%
|
$63,616
$8.06 P/Share
|
|
May 20
2025
|
Philip Astley Sparke Director |
SELL
Open market or private sale
|
Direct |
32,279
-2.25%
|
$258,232
$8.06 P/Share
|
|
May 20
2025
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,749
-2.84%
|
$29,992
$8.05 P/Share
|
|
May 20
2025
|
Emily Luisa Hill Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,535
-1.74%
|
$20,280
$8.05 P/Share
|
|
Apr 01
2025
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
166,667
+31.13%
|
-
|
|
Apr 01
2025
|
Andrew Schwendenman Chief Accounting Officer |
SELL
Grant, award, or other acquisition
|
Direct |
33,333
-31.77%
|
-
|
|
Apr 01
2025
|
Christopher Sarchi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+25.42%
|
-
|
|
Apr 01
2025
|
Emily Luisa Hill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+23.55%
|
-
|
|
Apr 01
2025
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+22.51%
|
-
|
|
Dec 16
2024
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.72%
|
$120,000
$12.42 P/Share
|
|
Nov 18
2024
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,207
-5.64%
|
$52,070
$10.78 P/Share
|
|
Nov 18
2024
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,246
-6.19%
|
$72,460
$10.78 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 302K shares |
|---|---|
| Exercise of conversion of derivative security | 3.17K shares |
| Open market or private sale | 120K shares |
|---|---|
| Grant, award, or other acquisition | 33.3K shares |